Zhejiang Dayang Biotech Group Co Total Assets
Zhejiang Dayang Biotech Group Co total assets. Based on the latest financial reports, Zhejiang Dayang Biotech Group Co (003017) holds total assets worth CN¥1.88 Billion CNY (≈ $274.95 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 003017 market cap for the company's overall valuation and market capitalisation.
Total Assets of Zhejiang Dayang Biotech Group Co (2013–2025)
Total assets of Zhejiang Dayang Biotech Group Co from 2013 to 2025. This chart illustrates how Zhejiang Dayang Biotech Group Co's total assets have evolved over time, based on quarterly financial data. See current stock price of Zhejiang Dayang Biotech Group Co for real-time trading data and today's change.
Zhejiang Dayang Biotech Group Co - Asset Composition Analysis
Zhejiang Dayang Biotech Group Co Total Assets Breakdown (December 2025)
Zhejiang Dayang Biotech Group Co total assets breakdown as of December 2025. Zhejiang Dayang Biotech Group Co's total assets of CN¥1.88 Billion consist of 42.4% current assets and 57.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 24.3% |
| Accounts Receivable | CN¥86.89 Million | 4.8% |
| Inventory | CN¥107.66 Million | 5.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥86.17 Million | 4.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Zhejiang Dayang Biotech Group Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Zhejiang Dayang Biotech Group Co (003017) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Dayang Biotech Group Co's current assets represent 42.4% of total assets in 2025, a decrease from 52.6% in 2013.
- Cash Position: Cash and equivalents constituted 24.3% of total assets in 2025, up from 12.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 6.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 5.9% of total assets.
Zhejiang Dayang Biotech Group Co Competitors by Total Assets
Key competitors of Zhejiang Dayang Biotech Group Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
S&D Co. Ltd.
KQ:260970
|
Korea | ₩130.72 Billion |
|
Suzhou Nanomicro Technology Co Ltd
SHG:688690
|
China | CN¥2.34 Billion |
|
Zhejiang Yongtai Technology Co Ltd
SHE:002326
|
China | CN¥11.10 Billion |
|
Solvac S.A.
BR:SOLV
|
Belgium | €2.73 Billion |
|
Shanghai Pret Composites
SHE:002324
|
China | CN¥13.10 Billion |
|
HeBei Jinniu Chemical Industry Co Ltd
SHG:600722
|
China | CN¥1.49 Billion |
|
Shandong Yanggu Huatai Chemical Co Ltd
SHE:300121
|
China | CN¥4.58 Billion |
|
Yunnan Yunwei Co Ltd Class A
SHG:600725
|
China | CN¥353.34 Million |
Zhejiang Dayang Biotech Group Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.23 | 1.29 | 3.20 |
| Quick Ratio | 1.05 | 1.06 | 2.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥146.61 Million | CN¥154.29 Million | CN¥459.10 Million |
Zhejiang Dayang Biotech Group Co - Advanced Valuation Insights
This section examines the relationship between Zhejiang Dayang Biotech Group Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.87 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 10.0% |
| Total Assets | CN¥1.82 Billion |
| Market Capitalization | $320.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Dayang Biotech Group Co's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhejiang Dayang Biotech Group Co's assets grew by 10.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhejiang Dayang Biotech Group Co (2013–2025)
The table below shows the annual total assets of Zhejiang Dayang Biotech Group Co from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.82 Billion ≈ $266.10 Million |
+9.97% |
| 2024-12-31 | CN¥1.65 Billion ≈ $241.97 Million |
+6.91% |
| 2023-12-31 | CN¥1.55 Billion ≈ $226.33 Million |
+2.57% |
| 2022-12-31 | CN¥1.51 Billion ≈ $220.66 Million |
+9.72% |
| 2021-12-31 | CN¥1.37 Billion ≈ $201.11 Million |
+11.84% |
| 2020-12-31 | CN¥1.23 Billion ≈ $179.81 Million |
+90.33% |
| 2019-12-31 | CN¥645.60 Million ≈ $94.47 Million |
+7.31% |
| 2018-12-31 | CN¥601.61 Million ≈ $88.03 Million |
+17.25% |
| 2017-12-31 | CN¥513.08 Million ≈ $75.08 Million |
+9.93% |
| 2016-12-31 | CN¥466.72 Million ≈ $68.30 Million |
+1.71% |
| 2015-12-31 | CN¥458.88 Million ≈ $67.15 Million |
-0.95% |
| 2014-12-31 | CN¥463.30 Million ≈ $67.80 Million |
+4.97% |
| 2013-12-31 | CN¥441.35 Million ≈ $64.58 Million |
-- |
About Zhejiang Dayang Biotech Group Co
Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally. The company offers inorganic chemicals, including potassium bicarbonate, ammonium chloride, manufactures and sales bicarbonate food and feed additives; veterinary drugs; potassium bicarbonate; and ammonium chloride. It also provides 2-chloro-6-fluorobenzoic acid, fluoro… Read more